TRIAL RESULTS · SIDE EFFECTS
Melanotan II side effects
ANSWER
No trial of Melanotan II has posted side-effect results on ClinicalTrials.gov (26 registered). Read on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
0
with an arm on Melanotan II, of 26 registered
Against placebo
0
placebo-controlled trials
People in those trials
0
on Melanotan II · 0 on placebo
Read
2026-10-03
ClinicalTrials.gov
TRIAL RESULTS
No posted side-effect results
None of the 26 registered trials of Melanotan II has posted side-effect results with an arm on Melanotan II to ClinicalTrials.gov. Read 2026-10-03.
REGISTERED STUDIES
26 registered clinical trials of Melanotan II
The 10 most recently updated are listed.
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Status: RECRUITING · Updated 2026-08-27 |
|---|---|
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Status: RECRUITING · Updated 2026-08-25 |
| NCT06124157 | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Status: RECRUITING · Updated 2026-08-24 |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Status: RECRUITING · Updated 2026-08-21 |
| NCT05431192 | Mind Your Heart-II Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-05 |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-04 |
| NCT02143414 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-04 |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Status: ACTIVE_NOT_RECRUITING · Updated 2026-07-29 |
| NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Status: RECRUITING · Updated 2026-06-12 |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Status: NOT_YET_RECRUITING · Updated 2026-06-09 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.